Soy‐derived isoflavones as chemo‐preventive agents targeting multiple signalling pathways for cancer prevention and therapy

Abstract

The chemopreventive and chemotherapeutic properties of soy and soy‐derived compounds, especially isoflavones, have been extensively studied in recent years. However, in contrast to their anticancer effects, such as cell growth inhibition, cell cycle arrest and apoptosis induction, isoflavones have also been found to promote the growth of cancer cells. Therefore, the aim of this comprehensive review article is to present the current state of knowledge regarding the molecular mechanisms by which soy‐derived isoflavones target multiple cellular signalling pathways in cancer cells. Our findings indicate that soy‐derived isoflavones act as, among other things, potent modulators of HOX transcript antisense RNA (HOTAIR)/SWI/SNF‐related matrix‐associated actin‐dependent regulator of chromatin subfamily B member 1 (SMARCB1), vascular endothelial growth factor (VEGF)/C–X–C motif chemokine ligand 12 (CXCL12)/C–X–C motif chemokine receptor type 4 (CXCR4), 17‐β‐oestradiol (E2)/oestrogen receptor‐α (ERα)/neuroglobin (NGB) and sonic hedgehog signalling pathways, epigenetic modulatory agents (i.a. miR‐155, miR‐34a and miR‐10a‐5p) and cancer stem cells and epithelial‐to‐mesenchymal transition inhibitors. The paper also discusses the latest epidemiological studies and clinical trials and provides an insight into recent extensive research on the chemo‐preventive and therapeutic potential of soy‐derived isoflavones.